Plasma indoleamine 2,3-dioxygenase and arginase type i may contribute to decreased blood t-cell count in hemodialysis patients

Renal Failure

Volumn 34, Issue 9, 2012, Pages 1118-1122

  Eleftheriadis, Theodoros ^a   Yiannaki, Efi ^b   Antoniadi, Georgia ^a   Liakopoulos, Vassilios ^a   Pissas, Georgios ^a   Galaktidou, Grammati ^b   Stefanidis, Ioannis ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Arginase type I; Hemodialysis; Indoleamine 2,3 dioxygenase; T cell

Indexed keywords

ARGINASE 1; INDOLEAMINE 2,3 DIOXYGENASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL;

ADAPTIVE IMMUNITY; APOPTOSIS; ARGINASE; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KIDNEY FAILURE, CHRONIC; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PROGNOSIS; RENAL DIALYSIS; T-LYMPHOCYTES;

EID: 84866423624     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2012.713297     Document Type: Article

References (32)

1. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semi Dialysis. 2007;20:440-451.
2. Smirnoff M, Patt C, Seckler B, Adler JJ. Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest. 1998;113:25-27.
3. Eleftheriadis T, Tsiaga P, Antoniadi G, et al. The value of serum antilipoarabinomannan antibody detection in the diagnosis of latent tuberculosis in hemodialysis patients. Am J Kidney Dis. 2005;46:706-712.
4. Kreft B, Klouche M, Kreft R, Kirchner H, Sack K. Low efficiency of active immunization against diphtheria in chronic hemodialysis patients. Kidney Int. 1997;52:212-216.
5. Friedman EA, Beyer MM, Hirsch SR, Schiffman G. Intact antibody response to pneumococcal capsular polysaccharides in uremia and diabetes. JAMA. 1980;244:2310-2311.
6. King NJ, Thomas SR. Molecules in focus: Indoleamine 2,3- dioxygenase. Int J Biochem Cell Biol. 2007;39:2167-2172.
7. Mulley WR, Nikolic-Paterson DJ. Indoleamine 2,3-dioxygenase in transplantation. Nephrology (Carlton). 2008;13:204-211.
8. Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: Focus on hematology. Blood. 2009;113:2394-2401.
9. Mellor AL, Munn DH. Ido expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762-774.
10. Mellor AL, Munn DH. Creating immune privilege: Active local suppression that benefits friends, but protects foes. Nat Rev Immunol. 2008;8:74-80.
11. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002;9:1069-1077.
12. Darcy CJ, Davis JS, Woodberry T, et al. An observational cohort study of the kynurenine to tryptophan ratio in sepsis: Association with impaired immune and microvascular function. PLoS One. 2011;6:e21185.
13. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9:162-174.
14. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem. 2002;277:21123-21129.
15. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007; 109:1568-1573.
16. Eleftheriadis T, Kartsios C, Yiannaki E, et al. Chronic inflammation and T cell zeta-chain downregulation in hemodialysis patients. Am J Nephrol. 2008;28:152-157.
17. Moline-Velazquez V, Cuervo H, Vila-Del Sol V, Ortega MC, Clemente D, de Castro F. Myeloid-derived suppressor cells limit the inflammation by promoting T lymphocyte apoptosis in the spinal cord of a murine model of multiple sclerosis. Brain Pathol. 2011;21:678-691.
18. Liu YY, Sun LC, Wei JJ, et al. Tumor cell-released TLR4 ligands stimulate Gr-1CD11bF4/80 cells to induce apoptosis of activated T cells. J Immunol. 2010;185:2773-2782.
19. Popovic PJ, Zeh III HJ, Ochoa JB. Arginine and immunity. J Nutr. 2007;137:1681S-1686S.
20. Ankersmit HJ, Deicher R, Moser B, et al. Impaired T cell proliferation, increased soluble death-inducing receptors and activation-induced T cell death in patients undergoing hemodialysis. Clin Exp Immunol. 2001;125:142-148.
21. Meier P, Dayer E, Blanc E, Wauters JP. Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. JASN. 2002;13:204-212.
22. Kurz P, Kohler H, Meuer S, Hutteroth T, Meyer zum Buschenfelde KH. Impaired cellular immune responses in chronic renal failure: Evidence for a T cell defect. Kidney Int. 1986;29:1209-1214.
23. Jenkinson CP, Grody WW, Cederbaum SD. Comparative properties of arginases. Comp Biochem Physiol B Biochem Mol Biol. 1996;114:107-132.
24. Yasuda K, Okuda K, Endo N, et al. Hypoaminotransferasemia in patients undergoing long-term hemodialysis: Clinical and biochemical appraisal. Gastroenterology. 1995;109:1295-1300.
25. Schefold JC, Zeden JP, Fotopoulou C, et al. Increased indoleamine 2,3-dioxygenase (ido) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: A possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant. 2009;24:1901-1908.
26. Eleftheriadis T, Liakopoulos V, Antoniadi G, Stefanidis I, Galaktidou G. Indoleamine 2,3-dioxygenase is increased in hemodialysis patients and affects immune response to hepatitis B vaccination. Vaccine. 2011;29:2242-2247.
27. Eleftheriadis T, Antoniadi G, Liakopoulos V, Stefanidis I, Galaktidou G. Plasma indoleamine 2,3-dioxygenase concentration is increased in hemodialysis patients and may contribute to the pathogenesis of coronary heart disease. Ren Fail. 2012;34:68-72.
28. Pawlak K, Brzosko S, Mysliwiec M, Pawlak D. Kynurenine, quinolinic acid - The new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis. 2009;204:561-566.
29. Eleftheriadis T, Liakopoulos V, Antoniadi G, Stefanidis I, Galaktidou G. Arginase type I as a marker of coronary heart disease in hemodialysis patients. Int Urol Nephrol. 2011;43:1187-1194.
30. Asano K, Sachs MS. Translation factor control of ribosome conformation during start codon selection. Genes Dev. 2007;21:1280-1287.
31. Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005;22:633-642.
32. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5:641-654.